BlackRock Inc. Buys 56,745 Shares of Endologix Inc (ELGX)

BlackRock Inc. boosted its stake in shares of Endologix Inc (NASDAQ:ELGX) by 1.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,093,047 shares of the medical instruments supplier’s stock after purchasing an additional 56,745 shares during the period. BlackRock Inc. owned 6.10% of Endologix worth $27,248,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ELGX. Quantitative Systematic Strategies LLC acquired a new stake in shares of Endologix in the fourth quarter valued at approximately $139,000. Teacher Retirement System of Texas acquired a new stake in shares of Endologix in the fourth quarter valued at approximately $144,000. JPMorgan Chase & Co. lifted its position in shares of Endologix by 211.2% in the third quarter. JPMorgan Chase & Co. now owns 109,380 shares of the medical instruments supplier’s stock valued at $488,000 after buying an additional 74,227 shares during the last quarter. GW&K Investment Management LLC lifted its position in shares of Endologix by 38.2% in the fourth quarter. GW&K Investment Management LLC now owns 218,106 shares of the medical instruments supplier’s stock valued at $1,167,000 after buying an additional 60,247 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its position in shares of Endologix by 5.0% in the third quarter. Schwab Charles Investment Management Inc. now owns 337,238 shares of the medical instruments supplier’s stock valued at $1,505,000 after buying an additional 15,929 shares during the last quarter.

How to Become a New Pot Stock Millionaire

ELGX has been the subject of a number of recent analyst reports. BidaskClub cut Endologix from a “buy” rating to a “hold” rating in a research report on Friday, December 15th. Zacks Investment Research raised Endologix from a “sell” rating to a “hold” rating in a research report on Monday, March 19th. Oppenheimer set a $5.00 price objective on Endologix and gave the company a “hold” rating in a research report on Thursday, February 22nd. ValuEngine cut Endologix from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. Finally, JPMorgan Chase cut Endologix from a “neutral” rating to an “underweight” rating in a research report on Tuesday, January 2nd. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $5.41.

Shares of NASDAQ ELGX opened at $4.11 on Friday. The company has a market cap of $354.16, a PE ratio of -8.56 and a beta of 0.32. The company has a debt-to-equity ratio of 2.77, a quick ratio of 1.62 and a current ratio of 2.36. Endologix Inc has a 1-year low of $3.75 and a 1-year high of $7.66.

Endologix (NASDAQ:ELGX) last announced its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.08) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.13. The company had revenue of $44.00 million for the quarter, compared to analyst estimates of $44.91 million. Endologix had a negative return on equity of 44.91% and a negative net margin of 36.65%. The firm’s quarterly revenue was down 7.3% compared to the same quarter last year. During the same quarter last year, the company earned ($0.30) earnings per share. equities research analysts predict that Endologix Inc will post -0.73 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.thelincolnianonline.com/2018/04/14/blackrock-inc-buys-56745-shares-of-endologix-inc-elgx.html.

About Endologix

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.

Institutional Ownership by Quarter for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply